The Treatment Landscape of Elderly Patients with Hormone Receptor-Positive Her2 Negative Advanced Breast Cancer: Current Perspectives and Future Directions.
breast cancer
comprehensive geriatric assessment
elderly
endocrine therapy
targeted agents
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
16 Sep 2023
16 Sep 2023
Historique:
received:
07
08
2023
revised:
26
08
2023
accepted:
14
09
2023
medline:
28
9
2023
pubmed:
28
9
2023
entrez:
28
9
2023
Statut:
epublish
Résumé
Breast cancer (BC) in elderly women is an increasing health issue due to demographic changes. BC tends to present later and may receive less than standard treatment options. More often, BC in elderly patients is endocrine-positive (HR+). The treatment of elderly patients with metastatic BC (mBC) represents a therapeutic challenge. In recent years, the treatment landscape of patients that are HR+/Her2-negative has changed due to the introduction in clinical practice of new targeted drugs, which have improved patient outcomes. Elderly patients are a small percentage of all patients enrolled in clinical trials and, to date, there are no standardized guidelines that define the best treatment option for this patient population. This can lead to undertreatment or overtreatment, impacting patient morbidity and mortality. Geriatric Assessment tools to tailor the treatment in elderly patients are underused because they are long and difficult to apply in a busy routine clinical practice. For all these reasons, there is an urgent need to produce data about the best treatment for elderly patients with HR+ mBC. Herein, we report data from randomized clinical trials and real-world evidence on the therapeutic options for HR+ Her2-negative mBC elderly patients and explore future treatment directions.
Identifiants
pubmed: 37762952
pii: jcm12186012
doi: 10.3390/jcm12186012
pmc: PMC10532156
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
Ann Oncol. 2021 Feb;32(2):208-217
pubmed: 33246021
N Engl J Med. 2017 Aug 10;377(6):523-533
pubmed: 28578601
Am J Clin Nutr. 1989 Sep;50(3):454-9
pubmed: 2773825
Nat Rev Clin Oncol. 2015 Oct;12(10):573-83
pubmed: 26122181
Lancet Oncol. 2018 Jun;19(6):e305-e316
pubmed: 29893262
Clin Cancer Res. 2018 May 15;24(10):2328-2341
pubmed: 29514843
J Clin Oncol. 2005 Jun 1;23(16):3830-42
pubmed: 15923576
Future Oncol. 2020 Apr;16(12):705-715
pubmed: 32223649
J Clin Oncol. 2009 Jun 10;27(17):2758-65
pubmed: 19403886
Breast Cancer Res Treat. 2021 Oct;189(3):689-699
pubmed: 34414532
J Clin Oncol. 2005 Mar 1;23(7):1348-9
pubmed: 15684313
Lancet. 2017 Dec 17;388(10063):2997-3005
pubmed: 27908454
Cancer Treat Rev. 2009 Oct;35(6):487-92
pubmed: 19481353
BMC Geriatr. 2020 Jul 6;20(1):231
pubmed: 32631254
N Engl J Med. 2019 May 16;380(20):1929-1940
pubmed: 31091374
N Engl J Med. 1999 Dec 30;341(27):2061-7
pubmed: 10615079
Biochemistry. 2010 Feb 16;49(6):1331-7
pubmed: 20030375
Clin Exerc Physiol. 2002 Feb;4(1):44-49
pubmed: 16946801
Cancer Discov. 2018 Sep;8(9):1176-1193
pubmed: 29991605
Ann Oncol. 2021 Sep;32(9):1148-1156
pubmed: 34116144
Nihon Ronen Igakkai Zasshi. 2006 Jan;43(1):27-34
pubmed: 16521795
N Engl J Med. 2019 Jul 11;381(2):121-131
pubmed: 31157964
Future Oncol. 2012 Jun;8(6):651-7
pubmed: 22764762
J Clin Oncol. 2003 Oct 1;21(19):3580-7
pubmed: 12913099
Cancer Discov. 2023 Mar 1;13(3):522
pubmed: 36661374
Cancer. 2004 Sep 15;101(6):1302-10
pubmed: 15316944
N Engl J Med. 2018 Jun 28;378(26):2465-2474
pubmed: 29949494
Biomed Res Int. 2016;2016:1381695
pubmed: 27807536
J Clin Oncol. 2017 Nov 10;35(32):3638-3646
pubmed: 28968163
N Engl J Med. 2018 Nov 15;379(20):1926-1936
pubmed: 30345905
Hum Pathol. 2021 Jan;107:80-86
pubmed: 33157125
J Clin Oncol. 2010 Sep 1;28(25):3922-8
pubmed: 20679609
N Engl J Med. 2022 Mar 10;386(10):942-950
pubmed: 35263519
J Natl Cancer Inst. 2014 Jan;106(1):djt319
pubmed: 24273215
Cancer Treat Rev. 2005 Aug;31(5):380-402
pubmed: 15967582
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
ESMO Open. 2020 Aug;5(4):
pubmed: 32817060
Elife. 2018 Nov 29;7:
pubmed: 30489256
J Clin Oncol. 2014 Aug 20;32(24):2595-603
pubmed: 25071125
Lancet. 2015 Oct 3;386(10001):1341-1352
pubmed: 26211827
J Clin Oncol. 2021 Feb 20;39(6):608-618
pubmed: 33444080
Clin Interv Aging. 2022 Sep 28;17:1445-1460
pubmed: 36199974
Lancet Healthy Longev. 2022 Jan;3(1):e54-e66
pubmed: 35047868
Lancet Oncol. 2021 Jul;22(7):e327-e340
pubmed: 34000244
J Clin Oncol. 2005 Nov 1;23(31):7794-803
pubmed: 16172456
Lancet Oncol. 2015 Jan;16(1):25-35
pubmed: 25524798
Crit Rev Oncol Hematol. 2008 Apr;66(1):65-74
pubmed: 17949989
Mol Cancer Res. 2016 Nov;14(11):1054-1067
pubmed: 27565181
Lancet Oncol. 2019 Jan;20(1):88-99
pubmed: 30509771
Clin Cancer Res. 2020 Dec 1;26(23):6149-6157
pubmed: 32988969
Breast Cancer Res. 2020 Aug 5;22(1):83
pubmed: 32758299
Breast Cancer Res Treat. 2010 May;121(1):1-11
pubmed: 19533338
Eur J Cancer Care (Engl). 2004 Dec;13(5):424-33
pubmed: 15606709
Expert Opin Pharmacother. 2023 Jun;24(8):887-900
pubmed: 37038927
J Clin Oncol. 2019 Nov 10;37(32):2974-2986
pubmed: 31329516
Front Pharmacol. 2022 Feb 11;13:752098
pubmed: 35222017
Mol Cancer Ther. 2008 Jul;7(7):2003-11
pubmed: 18645010
Onco Targets Ther. 2015 Nov 11;8:3323-8
pubmed: 26648736
N Engl J Med. 2014 Jul 31;371(5):424-33
pubmed: 24881730
Eur J Cancer. 2001 Oct;37 Suppl 7:S229-33
pubmed: 11887994
Oncologist. 2014 Apr;19(4):318-27
pubmed: 24682463
J Natl Cancer Inst. 2009 Sep 2;101(17):1174-81
pubmed: 19657108
Cancer Treat Rev. 2022 Sep;109:102432
pubmed: 35839531
Oncologist. 2000;5(3):224-37
pubmed: 10884501
Endocr Relat Cancer. 2010 Apr 21;17(2):415-30
pubmed: 20228125
Breast Cancer Res Treat. 2020 Sep;183(2):419-428
pubmed: 32683565
Semin Cancer Biol. 2020 Dec;67(Pt 2):171-179
pubmed: 32058059
Transl Cancer Res. 2020 Jan;9(Suppl 1):S146-S153
pubmed: 35117958
J Clin Oncol. 2005 Mar 1;23(7):1431-8
pubmed: 15684319
Breast Cancer Res Treat. 2018 Feb;167(3):659-669
pubmed: 29058175
Lancet Oncol. 2021 Apr;22(4):489-498
pubmed: 33794206
Lancet. 2013 Mar 9;381(9869):805-16
pubmed: 23219286
Clin Cancer Res. 2014 Apr 1;20(7):1757-1767
pubmed: 24398047
CA Cancer J Clin. 2006 Nov-Dec;56(6):323-53
pubmed: 17135691
Breast Cancer Res Treat. 2021 Apr;186(2):417-428
pubmed: 33392835
Lancet. 2023 May 27;401(10390):1773-1785
pubmed: 37086745
J Oncol Pract. 2018 Feb;14(2):85-94
pubmed: 29436306
N Engl J Med. 2016 Jul 21;375(3):209-19
pubmed: 27264120
Cancer Treat Rev. 2017 Sep;59:22-32
pubmed: 28719836
Med Sci Sports Exerc. 2003 Nov;35(11):1846-52
pubmed: 14600549
Expert Opin Pharmacother. 2011 Apr;12(6):945-60
pubmed: 21323593
N Engl J Med. 2023 Jun 1;388(22):2058-2070
pubmed: 37256976
Lancet Oncol. 2003 Apr;4(4):251-4
pubmed: 12681269
Cancers (Basel). 2021 Aug 25;13(17):
pubmed: 34503097
Crit Rev Oncol Hematol. 2000 Jan;33(1):45-56
pubmed: 10714961
N Engl J Med. 2019 Feb 21;380(8):741-751
pubmed: 30786188
N Engl J Med. 2022 Jul 7;387(1):9-20
pubmed: 35665782
N Engl J Med. 2019 Feb 14;380(7):617-628
pubmed: 30516102
Surg Clin North Am. 2018 Aug;98(4):819-833
pubmed: 30005776
J Clin Oncol. 2009 Aug 1;27(22):3611-9
pubmed: 19470941
Br J Cancer. 2004 Jun 14;90(12):2278-87
pubmed: 15162154
Lancet. 2011 Mar 12;377(9769):914-23
pubmed: 21376385
Cancer Epidemiol Biomarkers Prev. 2005 Jul;14(7):1588-95
pubmed: 16030088
N Engl J Med. 2020 Feb 6;382(6):514-524
pubmed: 31826360
Oncotarget. 2017 Jun 30;8(42):72950-72958
pubmed: 29069839
N Engl J Med. 2020 Dec 24;383(26):2557-2570
pubmed: 33369357
N Engl J Med. 2016 Nov 17;375(20):1925-1936
pubmed: 27959613
Mod Pathol. 2011 Jul;24(7):924-31
pubmed: 21552212
Ther Adv Med Oncol. 2018 Nov 20;10:1758835918809610
pubmed: 30479671
N Engl J Med. 2012 Nov 8;367(19):1783-91
pubmed: 23020162
Cells. 2020 Dec 28;10(1):
pubmed: 33379269
Semin Oncol Nurs. 2000 May;16(2):106-12
pubmed: 10842779
Oncotarget. 2015 Sep 8;6(26):22496-512
pubmed: 26101915
Breast Cancer Res. 2021 Mar 24;23(1):37
pubmed: 33761995
JAMA Oncol. 2019 Dec 1;5(12):1769-1773
pubmed: 31158272
Breast Cancer Res Treat. 2014 Feb;143(3):459-67
pubmed: 24362951
Clin Breast Cancer. 2022 Aug;22(6):601-610
pubmed: 35643624
NPJ Breast Cancer. 2023 May 20;9(1):41
pubmed: 37210417
J Clin Oncol. 2022 Oct 1;40(28):3246-3256
pubmed: 35584336
Eur J Cancer. 2018 Sep;101:123-133
pubmed: 30053671
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
N Engl J Med. 2012 Feb 9;366(6):520-9
pubmed: 22149876
Bone Marrow Transplant. 2020 Dec;55(12):2224-2233
pubmed: 32398784
Oncologist. 2019 Jun;24(6):e232-e240
pubmed: 30413667
Crit Rev Oncol Hematol. 2000 Jun;34(3):137-68
pubmed: 10838261
Cancer Treat Rev. 2023 Jun;117:102569
pubmed: 37146385
J Clin Oncol. 2009 Jun 20;27(18):2954-61
pubmed: 19349550
Lancet. 2011 Aug 27;378(9793):771-84
pubmed: 21802721
Breast Cancer Res Treat. 2011 Nov;130(2):477-87
pubmed: 21837479
Explor Target Antitumor Ther. 2022;3(1):27-36
pubmed: 36046357
N Engl J Med. 2018 Aug 23;379(8):753-763
pubmed: 30110579
J Clin Oncol. 2017 Sep 1;35(25):2875-2884
pubmed: 28580882
Breast Cancer Res Treat. 2014 Oct;147(3):473-85
pubmed: 25178514
Breast Cancer Res. 2018 May 2;20(1):37
pubmed: 29720233